News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
_256_384.jpg)
The platform will be a curated marketplace for sustainable-driven products by small-medium entrepreneurs and will encourage an autonomous marketplace
The company plans to raise US $ 15 million
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
This deal makes Meddo, one of the largest health-tech players in India
The government has taken all the effective measures to make healthcare affordable
Subscribe To Our Newsletter & Stay Updated
